Adverse events through 24 weeks in the subset of WOCBP (studies GS-US-320-0110 and GS-US-320-0108; week 96 integrated safety analysis set; reference 21).
Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial)
*Grade 3/4 adverse events summarised by MedDRA System Organ Class which were reported by 5 or more peoplepy: person yearsClinical outcomes by randomised arm.
